Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...

Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes. Conducted by ...

Candel Therapeutics, Inc. recently announced positive results from its clinical trials, highlighting the efficacy of its investigational therapies CAN-2409 and CAN-3110 in treating various cancers.

Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...